When first line treatments for neurological diseases such as Parkinson's Disease (PD) and Multiple Sclerosis (MS) have been around for years, it's understandable that when something new is approved, people want to try it...

As payer and stakeholder anger mounts, when will the oncology drug price bubble burst? Global cancer drug prices have increased by 10% every year between 1995 and 2013. That level of price inflation is not sustainable...

Are your value-added services (VAS) in oncology meeting the needs of payers as well as patients and physicians? Payers are increasingly taking interest in beyond-the-pill services that improve patient adherence,...

Achieving commercial success for orphan drugs requires specific strategies to be adopted, not least because market barriers are very different from those encountered when launching more common disease therapies. Lack of...

This report gives a unique insight into how US and European market access teams are organised and how they are focusing their time on a day-to-day basis. Market Access Team Structure and Function: Industry Survey 2017...

Most, if not all, pharma companies are slowly but surely transforming themselves into patient-centric organisations, but some are much further along the path than others. What have the pioneers done differently and what...

Customer engagement is generating a positive buzz across the pharmaceutical industry and that's proving to be a welcome change. Drug manufacturers are making excellent progress as they move away from the brand focus of...

Commercialisation of Biosimilars From bench to bedside, biosimilars continue to dominate boardroom discussions around the world. But after all the talking, what's the secret to success in this high stakes market?...